此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

将脐带血组织来源的间充质基质细胞加入 Ruxolitinib 治疗类固醇难治性急性移植物抗宿主病

2026年9月21日 更新者:M.D. Anderson Cancer Center

两种剂量的脐带血组织来源的间充质基质细胞联合 Ruxolitinib 与 Ruxolitinib 单独治疗类固醇难治性急性移植物抗宿主病的随机对照试验研究

This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.

ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.

研究类型

介入性

注册 (估计的)

24

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • M D Anderson Cancer Center
        • 接触:
        • 首席研究员:
          • Partow Kebriaei, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 至 80年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participants between the ages of 12 years and 80 years (inclusive).
  2. Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
  3. Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
  4. Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
  5. Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.

Exclusion Criteria:

  1. De novo chronic GVHD
  2. Isolated acute GVHD of skin
  3. Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
  4. Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
  5. Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  6. Adult and pediatric patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
  7. Participants with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
  8. Participants with known allergy to bovine or porcine products.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Arm 1 (ruxolitinib)

Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.

Given PO

其他名称:
  • 贾卡菲
  • INCB-18424
  • INCB18424
  • 口服 JAK 抑制剂 INCB18424
实验性的:Arm 2 (ruxolitinib, lower dose ds-MSCs)

Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

Given PO

其他名称:
  • 贾卡菲
  • INCB-18424
  • INCB18424
  • 口服 JAK 抑制剂 INCB18424

Given ds-MSCs IV

其他名称:
  • 细胞疗法
实验性的:Arm 3 (ruxolitinib, higher dose ds-MSCs)

Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.

Given PO

其他名称:
  • 贾卡菲
  • INCB-18424
  • INCB18424
  • 口服 JAK 抑制剂 INCB18424

Given ds-MSCs IV

其他名称:
  • 细胞疗法

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
因任何原因死亡
大体时间:积极研究治疗开始后 28 天内
积极研究治疗开始后 28 天内
不良事件发生率
大体时间:积极研究治疗开始后 28 天内
积极研究治疗开始后 28 天内
Response
大体时间:At day 28 from start of therapy on study

Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed.

At day 28 from start of therapy on study

次要结果测量

结果测量
措施说明
大体时间
每个器官的完全反应发生率
大体时间:长达 6 个月
长达 6 个月
每个器官非常好的部分反应的发生率
大体时间:长达 6 个月
长达 6 个月
每个器官的部分反应发生率
大体时间:长达 6 个月
长达 6 个月
器官反应的持久性
大体时间:长达 6 个月
长达 6 个月
非复发死亡率 (NRM) 的累积发生率
大体时间:治疗后 6 个月
治疗后 6 个月
原发疾病复发/进展的累积发生率
大体时间:6个月时
6个月时
总生存期
大体时间:从入组到因任何原因死亡,在 6 个月时评估
从入组到因任何原因死亡,在 6 个月时评估
无病生存
大体时间:从入组到任何原因导致的死亡或原发疾病的复发/进展,在 6 个月时进行评估
从入组到任何原因导致的死亡或原发疾病的复发/进展,在 6 个月时进行评估
任何级别细胞因子释放的发生率
大体时间:完成最后一次 MSC 输注研究药物后最多 28 天
完成最后一次 MSC 输注研究药物后最多 28 天
任何输注毒性的发生率
大体时间:每次脐带血-MSC输注后24小时内
每次脐带血-MSC输注后24小时内
Graft versus host disease status
大体时间:At days 7, 14, 21 and 28 post treatment

Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD).

At days 7, 14, 21 and 28 post treatment
Proportion of response
大体时间:At days 7, 14, 21 and 28 post treatment

Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies.

At days 7, 14, 21 and 28 post treatment
Time to complete response
大体时间:Up to 6 months

Will be estimated by the method of Kaplan and Meier.

Up to 6 months
Time to very good partial response
大体时间:Up to 6 months

Will be estimated by the method of Kaplan and Meier.

Up to 6 months
Time to partial response
大体时间:Up to 6 months

Will be estimated by the method of Kaplan and Meier.

Up to 6 months
Graft versus host disease-free survival
大体时间:At 6 months

Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint

At 6 months
Incidence of chronic graft versus host disease
大体时间:At 6 months after first mesenchymal stromal cells (MSC) infusion

Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months.

At 6 months after first mesenchymal stromal cells (MSC) infusion
Incidence of systemic infections
大体时间:28 days after last study drug

The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity.

28 days after last study drug
Incidence of toxicities
大体时间:Up to 28 days after completing last MSC infusion study drug

The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described.

Up to 28 days after completing last MSC infusion study drug

其他结果措施

结果测量
措施说明
大体时间
Cytokine biomarker analysis (optional)
大体时间:Up to 6 months

Will use cytokine biomarker assays to predict response to therapy.

Up to 6 months
Fecal samples analysis (optional)
大体时间:Up to 6 months

Will use fecal samples to assess microbiome and potential predictor for response to therapy.

Up to 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Partow Kebriaei, MD、M.D. Anderson Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年2月17日

初级完成 (估计的)

2032年3月31日

研究完成 (估计的)

2032年3月31日

研究注册日期

首次提交

2021年2月3日

首先提交符合 QC 标准的

2021年2月3日

首次发布 (实际的)

2021年2月8日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2019-1122
  • 2019-1122 (其他标识符:M D Anderson Cancer Center)
  • NCI-2020-13889 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • P01CA148600 (美国 NIH 拨款/合同)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅